1. Home
  2. LASR vs ZYME Comparison

LASR vs ZYME Comparison

Compare LASR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nLIGHT Inc.

LASR

nLIGHT Inc.

HOLD

Current Price

$48.01

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$23.55

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LASR
ZYME
Founded
2000
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
LASR
ZYME
Price
$48.01
$23.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$36.29
$32.75
AVG Volume (30 Days)
683.4K
900.2K
Earning Date
02-26-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$227,526,000.00
$134,481,000.00
Revenue This Year
$31.18
$64.19
Revenue Next Year
$11.31
$91.98
P/E Ratio
N/A
N/A
Revenue Growth
12.05
116.21
52 Week Low
$6.20
$9.03
52 Week High
$47.50
$28.49

Technical Indicators

Market Signals
Indicator
LASR
ZYME
Relative Strength Index (RSI) 80.69 43.44
Support Level $42.94 $22.80
Resistance Level $47.50 $24.80
Average True Range (ATR) 2.59 1.33
MACD 0.62 -0.20
Stochastic Oscillator 96.60 24.30

Price Performance

Historical Comparison
LASR
ZYME

About LASR nLIGHT Inc.

nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products, which includes semiconductor lasers, fiber lasers, and directed energy products; and Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: